Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bridge Medicines LLC manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. There is 1 pending office action currently active for this portfolio. This 1 action is being handled by a distinct examiner within a distinct art unit, representing a highly focused point of prosecution.
ENGLISH, CONNOR KENNEDY is identified as the busiest examiner for this portfolio. This examiner is responsible for the 1 pending office action currently in the system. For a practitioner, this means that all active prosecution efforts are directed toward a sole individual. The concentration in a distinct art unit indicates a specific technical focus within Biotechnology & Pharmaceuticals.
The presence of a distinct examiner across the portfolio's pending matters allows for a very targeted communication strategy. Practitioners can dedicate their resources to understanding the specific preferences of ENGLISH, CONNOR KENNEDY. Since the busiest examiner pending count matches the total pending office actions, the prosecution environment is streamlined and free from the complexities of multiple examiner interactions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ENGLISH, CONNOR KENNEDY | 1 | 59.3% | +50.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17757492 | INHIBITORS OF ENL/AF9 YEATS | ENGLISH, CONNOR KENNEDY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17757492 | INHIBITORS OF ENL/AF9 YEATS | ENGLISH, CONNOR KENNEDY | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17757492 | INHIBITORS OF ENL/AF9 YEATS | ENGLISH, CONNOR KENNEDY | 1625 | §102§112Other | Non-Final OA | — | Pending | Jun 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBridge Medicines LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Connor Kennedy English has the most, with 1 of Bridge Medicines LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.